{"analyses":[{"ciLowerLimit":"0.110","ciPctValue":"95","ciUpperLimit":"0.687","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","paramType":"Hazard Ratio (HR)","paramValue":"0.274","statisticalComment":"Adjusted for cancer type stratification factor and screening uNTx level","statisticalMethod":"Regression, Cox","testedNonInferiority":false},{"ciLowerLimit":"0.076","ciPctValue":"95","ciUpperLimit":"0.523","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.199","statisticalComment":"Adjusted for cancer type stratification factor and screening uNTx level","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25.","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"NUMBER","populationDescription":"Treatment Phase Primary Analysis Subset. Median was not reached in at least 1 treatment arm. In lieu of the median, the number of subject whose uNTX (corrected by creatinine) less than 50nmol/mmol is presented.","reportingStatus":"POSTED","timeFrame":"Day 1, week 25","title":"Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol","type":"SECONDARY","unitOfMeasure":"Participants"}